Ifm_05-may 2022 Apr 2026

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. IFM_05-May 2022

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo. To determine if continuous low-dose chemotherapy after a